TY - JOUR
T1 - Targeting mammalian target of rapamycin (mTOR) for health and diseases
AU - Tsang, Chi Kwan
AU - Qi, Haiyan
AU - Liu, Leroy F.
AU - Zheng, X. F.Steven
N1 - Funding Information:
We apologize for being unable to cite all the relevant publications due to space constraint. Research in the authors’ laboratories was supported by grants from the National Institutes of Health (L.F.L. and X.F.S.Z).
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2007/2
Y1 - 2007/2
N2 - The macrolide rapamycin is used clinically to treat graft rejection and restenosis. Mammalian target of rapamycin (mTOR) is a central controller of cellular and organism growth that integrates nutrient and hormonal signals, and regulates diverse cellular processes. New studies have linked mTOR to several human diseases including cancer, diabetes, obesity, cardiovascular diseases and neurological disorders. Recent data have also revealed that mTOR is involved in the regulation of lifespan and in age-related diseases. These findings demonstrate the importance of growth control in the pathology of major diseases and overall human health, and underscore the therapeutic potential of the mTOR pathway.
AB - The macrolide rapamycin is used clinically to treat graft rejection and restenosis. Mammalian target of rapamycin (mTOR) is a central controller of cellular and organism growth that integrates nutrient and hormonal signals, and regulates diverse cellular processes. New studies have linked mTOR to several human diseases including cancer, diabetes, obesity, cardiovascular diseases and neurological disorders. Recent data have also revealed that mTOR is involved in the regulation of lifespan and in age-related diseases. These findings demonstrate the importance of growth control in the pathology of major diseases and overall human health, and underscore the therapeutic potential of the mTOR pathway.
UR - http://www.scopus.com/inward/record.url?scp=33846569938&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846569938&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2006.12.008
DO - 10.1016/j.drudis.2006.12.008
M3 - Review article
C2 - 17275731
AN - SCOPUS:33846569938
SN - 1359-6446
VL - 12
SP - 112
EP - 124
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 3-4
ER -
